Unknown

Dataset Information

0

MTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.


ABSTRACT: Gastrointestinal cancers are frequently associated with chronic inflammation and excessive secretion of IL-6 family cytokines, which promote tumorigenesis through persistent activation of the GP130/JAK/STAT3 pathway. Although tumor progression can be prevented by genetic ablation of Stat3 in mice, this transcription factor remains a challenging therapeutic target with a paucity of clinically approved inhibitors. Here, we uncovered parallel and excessive activation of mTOR complex 1 (mTORC1) alongside STAT3 in human intestinal-type gastric cancers (IGCs). Furthermore, in a preclinical mouse model of IGC, GP130 ligand administration simultaneously activated mTORC1/S6 kinase and STAT3 signaling. We therefore investigated whether mTORC1 activation was required for inflammation-associated gastrointestinal tumorigenesis. Strikingly, the mTORC1-specific inhibitor RAD001 potently suppressed initiation and progression of both murine IGC and colitis-associated colon cancer. The therapeutic effect of RAD001 was associated with reduced tumor vascularization and cell proliferation but occurred independently of STAT3 activity. We analyzed the mechanism of GP130-mediated mTORC1 activation in cells and mice and revealed a requirement for JAK and PI3K activity but not for GP130 tyrosine phosphorylation or STAT3. Our results suggest that GP130-dependent activation of the druggable PI3K/mTORC1 pathway is required for inflammation-associated gastrointestinal tumorigenesis. These findings advocate clinical application of PI3K/mTORC1 inhibitors for the treatment of corresponding human malignancies.

SUBMITTER: Thiem S 

PROVIDER: S-EPMC3561832 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


Gastrointestinal cancers are frequently associated with chronic inflammation and excessive secretion of IL-6 family cytokines, which promote tumorigenesis through persistent activation of the GP130/JAK/STAT3 pathway. Although tumor progression can be prevented by genetic ablation of Stat3 in mice, this transcription factor remains a challenging therapeutic target with a paucity of clinically approved inhibitors. Here, we uncovered parallel and excessive activation of mTOR complex 1 (mTORC1) alon  ...[more]

Similar Datasets

| S-EPMC4079758 | biostudies-literature
2013-01-29 | E-GEOD-35808 | biostudies-arrayexpress
2013-01-29 | GSE35808 | GEO
| S-EPMC2857533 | biostudies-literature
| S-EPMC3633657 | biostudies-literature
| S-EPMC4389904 | biostudies-literature
| S-EPMC4101061 | biostudies-literature
| S-EPMC6791707 | biostudies-literature
| S-EPMC6343133 | biostudies-literature
2014-07-23 | E-GEOD-55587 | biostudies-arrayexpress